Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 371 across all filing types
Latest filing 2026-06-01 M&A Activity
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 90% confidence The document is a Form 8-K “Current Report” disclosing Item 1.01 Entry into a Material Definitive Agreement—a $1.55 billion asset purchase agreement. This is a corporate transaction announcement (asset sale/acquisition) rather than a proxy, tender-offer form, or simple regulatory filing without substantive transaction details. It does not contain full financial statements (so not an Interim or Annual Report), nor is it merely a report publication announcement. It is clearly an M&A announcement of an asset purchase, fitting the “M&A Activity” category. Therefore, it is classified as TAR.
2026-06-01 English
S-8 - Edgewise Therapeutics, Inc. (0001710072) (Filer)
Share Issue/Capital Change Classification · 87% confidence The document is an SEC Form S-8 registration statement under the Securities Act of 1933 for the company’s 2021 Equity Incentive Plan and Employee Stock Purchase Plan. A Form S-8 registers new securities issuance under employee benefit plans. This is not an annual or quarterly report, earnings release, or management change notice, but rather a capital issuance notification. Therefore it should be classified as a Share Issue/Capital Change filing.
2026-05-07 English
8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed under Item 2.02 “Results of Operations and Financial Condition,” stating that the company issued a press release with its first quarter 2026 financial results. This matches the definition of an initial announcement of quarterly financial results (Earnings Release). Q1 2026
2026-05-07 English
10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
DEF 14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
Regulatory Filings
2026-03-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.